Publication: The effects of the renin-angiotensin-aldosterone system blockers on serum ischemia-modified albumin levels in autosomal dominant polycystic kidney disease
dc.contributor.author | Ermurat, Selime | |
dc.contributor.author | Güllülü, Mustafa | |
dc.contributor.author | Sarandöl, Emre | |
dc.contributor.buuauthor | GÜLLÜLÜ, MUSTAFA | |
dc.contributor.buuauthor | SARANDÖL, EMRE | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı. | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Klinik Biyokimya Anabilim Dalı. | |
dc.contributor.researcherid | JGS-9425-2023 | |
dc.contributor.researcherid | DXM-3644-2022 | |
dc.date.accessioned | 2024-09-18T13:18:08Z | |
dc.date.available | 2024-09-18T13:18:08Z | |
dc.date.issued | 2022-01-23 | |
dc.description.abstract | Background Among one of the common hereditary causes of chronic kidney disease is autosomal-dominant polycystic kidney disease (ADPKD), and its incidence rate is reported as one between 500 and 1.000 individuals. The most common complications of ADPKD are hypertension (HT) and end-stage renal disease (ESRD). HT occurring in the early stage of ADPKD leads to deteriorations in renal function. Aims It was aimed to investigate the ischemia-modified albumin (IMA) levels and the effect of renin-angiotensin-aldosterone system (RAAS) blockers on serum IMA levels in patients with ADPKD. Methods One hundred and fifteen patients were included as ADPKD (n = 50), HT (n = 35), and healthy control (HC) groups (n = 30). Patients with ADPKD and HT were divided into two subgroups as RAAS blocker-users and non-users. Results Serum IMA levels were detected as 0.42 (0.17-0.80) in ADPKD and 0.28 (0.04-0.51) in HT and 0.36 (0.22-0.56) in HC groups as absorbance units (ABSU), and the highest serum IMA level was seen in Group ADPKD. Serum IMA levels were 0.33 +/- 0.14 in RAAS blocker-users and 0.41 +/- 0.11 ABSU in non-users with ADPKD. Serum IMA levels were witnessed to be significantly lower in RAAS blocker-users in Groups ADPKD (p = 0.038) and HT (p = 0.004), compared to non-users. Given basal and 6-month values of those with ADPKD, the levels of serum IMA within 6 months were significantly lower (p = 0.002). Conclusions We consider that serum IM levels should be assessed in oxidative stress (OS)-related conditions, such as ADPKD, and RAAS blockers may be effective in reducing serum IMA levels in ADPKD and HT patients. | |
dc.identifier.doi | 10.1007/s11845-022-02925-y | |
dc.identifier.endpage | 2783 | |
dc.identifier.issn | 0021-1265 | |
dc.identifier.issue | 6 | |
dc.identifier.startpage | 2777 | |
dc.identifier.uri | https://doi.org/10.1007/s11845-022-02925-y | |
dc.identifier.uri | https://link.springer.com/article/10.1007/s11845-022-02925-y | |
dc.identifier.uri | https://hdl.handle.net/11452/44906 | |
dc.identifier.volume | 191 | |
dc.identifier.wos | 000745754300001 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Springer London Ltd | |
dc.relation.journal | Irish Journal of Medical Science | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Oxidative stress | |
dc.subject | Endothelial dysfunction | |
dc.subject | Asymmetric dimethylarginine | |
dc.subject | Insulin-resistance | |
dc.subject | Progression | |
dc.subject | Blockade | |
dc.subject | Damage | |
dc.subject | Autosomal dominant polycystic kidney disease | |
dc.subject | Ischemia modified albumin | |
dc.subject | Oxidative stress | |
dc.subject | Renin-angiotensin-aldosterone blockade | |
dc.subject | General & internal medicine | |
dc.title | The effects of the renin-angiotensin-aldosterone system blockers on serum ischemia-modified albumin levels in autosomal dominant polycystic kidney disease | |
dc.type | Article | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 47f5ec68-c479-4f62-9aed-37ba604a689c | |
relation.isAuthorOfPublication | 9529fb52-20cd-4fb3-9767-19121683aa62 | |
relation.isAuthorOfPublication.latestForDiscovery | 47f5ec68-c479-4f62-9aed-37ba604a689c |